全文获取类型
收费全文 | 3260篇 |
免费 | 186篇 |
国内免费 | 220篇 |
出版年
2023年 | 43篇 |
2022年 | 74篇 |
2021年 | 86篇 |
2020年 | 72篇 |
2019年 | 91篇 |
2018年 | 107篇 |
2017年 | 56篇 |
2016年 | 65篇 |
2015年 | 76篇 |
2014年 | 143篇 |
2013年 | 209篇 |
2012年 | 107篇 |
2011年 | 162篇 |
2010年 | 129篇 |
2009年 | 135篇 |
2008年 | 168篇 |
2007年 | 171篇 |
2006年 | 146篇 |
2005年 | 144篇 |
2004年 | 144篇 |
2003年 | 110篇 |
2002年 | 105篇 |
2001年 | 66篇 |
2000年 | 87篇 |
1999年 | 90篇 |
1998年 | 80篇 |
1997年 | 70篇 |
1996年 | 71篇 |
1995年 | 65篇 |
1994年 | 73篇 |
1993年 | 66篇 |
1992年 | 55篇 |
1991年 | 48篇 |
1990年 | 35篇 |
1989年 | 28篇 |
1988年 | 37篇 |
1987年 | 21篇 |
1986年 | 17篇 |
1985年 | 31篇 |
1984年 | 32篇 |
1983年 | 13篇 |
1982年 | 27篇 |
1981年 | 21篇 |
1980年 | 13篇 |
1979年 | 18篇 |
1978年 | 13篇 |
1976年 | 11篇 |
1975年 | 8篇 |
1974年 | 7篇 |
1973年 | 6篇 |
排序方式: 共有3666条查询结果,搜索用时 125 毫秒
991.
Oral vaccination requires an antigen delivery vehicle to protect the antigen and to enhance translocation of the antigen to the mucosa-associated lymphoid tissue. A variety of antigen delivery vehicles including liposomes have been studied for mucosal immunization. The advantages of liposome formulations are their particulate form and the ability to accommodate immunomodulators and targeting molecules in the same package. Many conventional liposomes are variably unstable in acids, pancreatic juice and bile. Nevertheless, carefully designed liposomes have demonstrated an impressive efficacy in inducing mucosal IgA responses, compared to free antigens and other delivery vehicles. However, liposomes as an oral vaccine vehicle are not yet optimized. To design liposomes that are stable in the harsh intestinal environment and are efficiently taken up by the M cells remains a challenge. This review summarizes recent research efforts using liposomes as an antigen carrier for oral vaccines with practical attention to liposome designs and interaction with the M cells. 相似文献
992.
The induction of effective cellular and humoral immune responses against protein antigens is of major importance in vaccination strategies against infectious diseases and cancer. Immunization with protein alone in general does not result in efficient induction of cytotoxic T lymphocyte (CTL) and antibody responses. Numerous other immunization strategies have been explored. In this review we will discuss a number of lipid-based antigen delivery systems suitable for the induction of CTL responses. These systems comprise reconstituted virus envelopes (virosomes), liposomes, and immune-stimulating complexes (ISCOMs). We will concentrate on delivery of the protein antigen ovalbumin (OVA) since extensive studies with this antigen have been performed for all of the systems discussed, allowing direct comparison of antigen delivery efficiency. Stimulation of CTL activity requires processing of the antigen in the cytosol of antigen-presenting cells (APCs) and presentation of antigenic peptides on surface major histocompatibility class I complexes (MHC class I). In vitro, the ability of antigen delivery systems to induce MHC class I presentation indeed correlates with their capacity to deliver antigen to the cytosol of cells. This capacity appears to be less important for the induction of cytotoxic T lymphocytes in vivo. Instead, other properties of the antigen delivery system like activation of APCs and induction of T helper cells play a more prominent role. Fusion-active virosomes appear to be a very potent system for induction of CTL activity, most likely since virosomes combine efficient delivery of antigen with general stimulation of the immune system. 相似文献
993.
Anthrax toxin: a tripartite lethal combination 总被引:12,自引:0,他引:12
Ascenzi P Visca P Ippolito G Spallarossa A Bolognesi M Montecucco C 《FEBS letters》2002,531(3):384-388
Anthrax is a severe bacterial infection that occurs when Bacillus anthracis spores gain access into the body and germinate in macrophages, causing septicemia and toxemia. Anthrax toxin is a binary A-B toxin composed of protective antigen (PA), lethal factor (LF), and edema factor (EF). PA mediates the entry of either LF or EF into the cytosol of host cells. LF is a zinc metalloprotease that inactivates mitogen-activated protein kinase kinase inducing cell death, and EF is an adenylyl cyclase impairing host defences. Inhibitors targeting different steps of toxin activity have recently been developed. Anthrax toxin has also been exploited as a therapeutic agent against cancer. 相似文献
994.
The serine repeat antigen (SERA) of Plasmodium falciparum is a blood stage malaria vaccine candidate. It has been shown that 120 kDa SERA was proteolytically processed into N-terminal 47 kDa fragment (P47), central 56 kDa fragment (P56) that was further converted to 50 kDa (P50), and C-terminal 18 kDa fragment (P18). Here, we have examined the processing of SERA and the localization of its processed fragments by using mouse antibodies directed against recombinant proteins corresponding to different domains of SERA. Western blot analysis showed that all the processing events occurred inside parasitized erythrocytes at the stage just prior to the schizont rupture, that P47 was further processed into two 25 kDa fragments and that the two fragments, which were linked to P18 through disulfide bonds, were associated with the merozoite. In contrast, P50 was completely shed into culture medium and absent from the merozoite. This observation was further supported by the results of indirect immunofluorescence assay. These results could account for the findings that antibodies against P47 were inhibitory to the parasite growth in vitro but those against P50 were not. Finally, we demonstrated that the further processing of P47 is allelic type-dependent. The results of the present study would help in vaccine designing based on SERA. 相似文献
995.
In this paper we present an extension of cure models: to incorporate a longitudinal disease progression marker. The model is motivated by studies of patients with prostate cancer undergoing radiation therapy. The patients are followed until recurrence of the prostate cancer or censoring, with the PSA marker measured intermittently. Some patients are cured by the treatment and are immune from recurrence. A joint-cure model is developed for this type of data, in which the longitudinal marker and the failure time process are modeled jointly, with a fraction of patients assumed to be immune from the endpoint. A hierarchical nonlinear mixed-effects model is assumed for the marker and a time-dependent Cox proportional hazards model is used to model the time to endpoint. The probability of cure is modeled by a logistic link. The parameters are estimated using a Monte Carlo EM algorithm. Importance sampling with an adaptively chosen t-distribution and variable Monte Carlo sample size is used. We apply the method to data from prostate cancer and perform a simulation study. We show that by incorporating the longitudinal disease progression marker into the cure model, we obtain parameter estimates with better statistical properties. The classification of the censored patients into the cure group and the susceptible group based on the estimated conditional recurrence probability from the joint-cure model has a higher sensitivity and specificity, and a lower misclassification probability compared with the standard cure model. The addition of the longitudinal data has the effect of reducing the impact of the identifiability problems in a standard cure model and can help overcome biases due to informative censoring. 相似文献
996.
Celso A. Reis Tina Sørensen Ulla Mandel Leonor David Ekaterina Mirgorodskaya Peter Roepstorff Jan Kihlberg John-Erik Stig Hansen Henrik Clausen 《Glycoconjugate journal》1998,15(1):51-62
In an attempt to raise anti-Tn antibodies, an -N-acetyl-D-galactosamine glycosylated peptide based on the tandem repeat of the intestinal mucin MUC2 was used as an immunogen. The MUC2 peptide (PTTTPISTTTMVTPTPTPTC) was glycosylated in vitro using concentrated -N-acetylgalactosaminyltransferases activity from porcine submaxillary glands which resulted in the incorporation of 8–9 mol of Ga/NAc. Rabbits and mice developed specific anti-MUC2-GalNAc glycopeptide antibodies and no detectable anti-Tn antibodies. Anti-glycopeptide antibodies did not show reactivity with the unglycosylated MUC2 peptide or with other GalNAc glycosylated peptides. A mouse monoclonal antibody (PMH1) representative of the observed immune response was generated and its immunohistological reactivity analysed in normal tissues. PMH1 reacted similarly to other anti-MUC2 peptide antibodies. However, in some cells the staining was not restricted to the supranuclear area but extended to the entire cytoplasm. In addition, PMH1 reacted with purified colonic mucin by Western blot analysis suggesting that PMH1 reacted with some glycoforms of MUC2. The present work presents a useful approach for development of anti-mucin antibodies directed to different glycoforms of individual mucins. 相似文献
997.
Valery Kudryashov Govindaswami Ragupathi In Jong Kim Michael E Breimer Samuel J Danishefsky Philip O Livingston Kenneth O Lloyd 《Glycoconjugate journal》1998,15(3):243-249
Globo H (Fuc12Gal13GalNAc13Gal14Gal14Glc) is a carbohydrate structure that shows enhanced expression in many human carcinomas. From mice immunized with a globo H-KLH (keyhole limpet hemocyanin) synthetic conjugate an IgG3 monoclonal antibody (mAb VK-9) was derived that recognizes the globo H structure. Serological analysis showed that the minimal structure recognized by this mAb was the tetrasaccharide sequence Fuc12Gal13GalNAc13Gal. An isomeric structure with an internal GalNAc linkage was also recognized but less efficiently. mAb VK-9 did not react with many related structures, such as galactosylgloboside, globoside, H type 1, H type 2 blood group structures or fucosyl-gangliotetraosyl ceramide, but did react weakly with globo A ceramide. Not only did mAb VK-9 react with carbohydrate-protein conjugates but it could also recognize globo H-ceramide and human tumor cells expressing globo H. These results suggest that globo H-KLH could be explored as a vaccine in the treatment of carcinoma patients. 相似文献
998.
Mark R. Patrick Kerry A. Chester G. A. Pietersz 《Cancer immunology, immunotherapy : CII》1998,46(4):229-237
The major limitations of monoclonal antibody conjugates as therapeutic agents have been their poor tumour targeting, inadequate
tumour penetration and immunogenicity. More even and deeper tissue penetration has been demonstrated with smaller antibody
fragments. The smaller size and absence of an Fc segment may contribute to a lowered immunogenicity with single-chain antibodies
(scFv) and also permit their recombinant engineering and bacterial expression. We describe the successful engineering, expression
and pre-clinical characterisation of a phosphorylatable “kemptide” (Leu-Arg-Arg-Ala-Ser-Gly) anti-carcinoembryonic antigen
(anti-CEA) scFv (PKS-scFv), for use as a radioimmunotherapeutic agent. Specifically, a yield of 6 mg/l induced culture was
obtained. Site-specific phosphorylation was demonstrated without loss of specificity. In vitro assays revealed a selective
cytotoxicity of 32P-PKS-scFv for high-CEA-expressing LS-174T cells compared to the low-CEA-expressing HT-29 cells, with a rapid internalisation
rate.
Received: 20 March 1997 / Accepted: 5 February 1998 相似文献
999.
ImmunoPCRcombinesthehighsensitivityofPCRwiththespecificityofantibodyantigeninteraction.UsingimmunoPCR,asfewas600moleculesofimmobilizedantigen(bovineserumalbumin)havebeendetected[1].ThemostimportantstepinimmunoPCRistheconstructionofthegeneprobe.Sanoetal.[1,2]c… 相似文献
1000.
Since the end of 2001, we have conducted a project to isolate and determine entire sequences of mouse cDNA clones which encode the polypeptides corresponding to human KIAA proteins. Towards the ultimate goal of this project to clarify the biological functions of KIAA genes, we have set production of antibodies against mouse KIAA gene products based on their sequence information as the next important stage. As the first step, we developed a high-throughput system utilizing shotgun clones generated during entire sequencing of mouse KIAA cDNAs. The system consists of the following three parts: (1) Shotgun clones encoding regions suitable for production of antigens were selected using a newly developed browser system; (2) the protein-coding sequences of the selected shotgun clones were transferred into an expression vector by in vitro recombination-assisted method in a 96-well format, and expressed as glutathione S-transferase fusion proteins in Escherichia coli; and (3) the solubility of the recombinant antigens were preliminarily assessed in a small-scale culture and then large-scale production and purification was performed using glutathione-affinity beads or retrieval from polyacrylamide gels depending on their solubility. Using these systems, we successfully produced and purified 400 antigens for production of mKIAA antibodies to date. 相似文献